Company Filing History:
Years Active: 1983-1993
Title: Hirozumi Eto: Innovator in Cancer Research
Introduction
Hirozumi Eto is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the field of cancer research through his innovative inventions. With a total of 2 patents, his work focuses on developing agents that combat drug-resistant tumor cells.
Latest Patents
Eto's latest patents include a compound known as 1,4-dihydropyridine-4-aryl-2,6-dimethyl-3,5-dicarboxylates, which is useful as an agent against drug-resistant tumor cells. This compound is represented by a specific formula where R¹ is an aryl group that may be substituted. Additionally, he has developed a new process for preparing N-acylcarnosine. This process involves reacting histidine with 3-acylaminopropionic acid reactive derivatives under basic conditions, utilizing various chemical derivatives.
Career Highlights
Throughout his career, Hirozumi Eto has worked with prominent organizations such as Ajinomoto Co., Ltd. and the Japanese Foundation for Cancer Research. His work in these institutions has allowed him to focus on innovative solutions in the fight against cancer.
Collaborations
Eto has collaborated with esteemed colleagues, including Chikahiko Eguchi and Kouzou Toyota. These partnerships have further enhanced his research and development efforts in the field.
Conclusion
Hirozumi Eto's contributions to cancer research through his patents and collaborations highlight his dedication to innovation in medicine. His work continues to pave the way for advancements in treatments for drug-resistant tumors.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.